T.N. Glasnov et al. / Tetrahedron 64 (2008) 2035e2041
2041
4
.5. Ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-
D. R. S. Mini-Rev. Med. Chem. 2003, 3, 449; (d) Shipe, W. D.; Wolken-
berg, S. E.; Lindsley, C. W. Drug Discov. Today: Technol. 2005, 2,
tetrahydropyrimidine-5-carboxylate (monastrol, 1):
optimized protocol
1
55; (e) Kappe, C. O.; Dallinger, D. Nature Rev. Drug Discov. 2006, 5, 51.
6
. (a) Evans, M.; Ring, J.; Schoen, A.; Bell, A.; Edwards, P.; Berthelot, D.;
Nicewonger, R.; Baldino, C. M. Tetrahedron Lett. 2003, 44, 9337; (b) Tye,
H.; Whittaker, M. Org. Biomol. Chem. 2004, 2, 813; (c) McLean, N. J.;
Tye, H.; Whittaker, M. Tetrahedron Lett. 2004, 45, 993; (d) Gopalsamy,
A.; Shi, M.; Nilakantan, R. Org. Process Res. Dev. 2007, 11, 450; (e)
Sarotti, A. M.; Spanevello, R. A.; Su a´ rez, A. G. Green Chem. 2007, 9,
In a 10 mL Pyrex microwave vial, 3-hydroxybenzaldehyde
(
100 mg, 0.82 mmol, 1 equiv), ethyl acetoacetate (157 mL,
.23 mmol, 1.5 equiv), thiourea (60.7 mg, 0.82 mmol, 1 equiv),
and LaCl (24.5 mg, 0.082 mmol, 0.10 equiv) were added to
1
3
1
137.
1 mL anhydrous ethanol. After magnetic stirring for 2 min,
the vial was closed, placed in the microwave cavity, and irradi-
7
. (a) Biginelli, P. Gazz. Chim. Ital. 1893, 23, 360; (b) Kappe, C. O. Eur. J.
Med. Chem. 2000, 35, 1043; (c) Kappe, C. O. Acc. Chem. Res. 2000, 33,
879; (d) Kappe, C. O. Multicomponent Reactions; Zhu, J., Bienayme, H.,
Eds.; Wiley-VCH: Weinheim, 2005; p 95.
ꢀ
ated at 140 C for 30 min (fixed hold time). After the reaction
was finished, the solvent was removed under reduced pressure
and the residue subjected to silica gel chromatography (chloro-
8
. (a) Mayer, T. U.; Kapoor, T. M.; Haggarty, S. J.; King, R. W.; Schreiber,
S. L.; Mitchison, T. J. Science 1999, 286, 971; (b) Haggarty, S. J.; Mayer,
T. U.; Miyamoto, D. T.; Fathi, R.; King, R. W.; Mitchison, T. J.; Schreiber,
S. L. Chem. Biol. 2000, 7, 275; (c) For a recent review on mitotic kinesin
inhibitors, see: Sarli, V.; Giannis, A. ChemMedChem 2006, 1, 293.
. Dallinger, D.; Kappe, C. O. Nat. Protoc. 2007, 2, 317.
form/acetone¼5/1), resulting in the isolation of the pure product
1
in 82% yield. H NMR (360 MHz, CDCl ): d 1.12 (t, J¼6.9 Hz,
3
3
1
9
1
H), 2.27 (s, 3H), 4.02 (q, J¼6.6 Hz, 2H), 5.51 (d, J¼1.44 Hz,
9
H), 6.61e6.70 (m, 3H), 7.06e7.17 (m, 1H), 9.44 (s, 1H),
9
.60 (s, 1H), 10.29 (s, 1H). Mp 183e185 C (MeCN), lit. mp
1
0. For general microwave-assisted reaction optimization and library synthe-
sis of dihydropyrimidines via the Biginelli reaction, see: (a) Stadler, A.;
Kappe, C. O. J. Comb. Chem. 2001, 3, 624; (b) Dallinger, D.; Kappe,
C. O. Nat. Protoc. 2007, 2, 1713.
ꢀ
ꢀ
84e186 C.
Acknowledgements
11. (a) Dondoni, A.; Masso, A.; Sabbatini, S. Tetrahedron Lett. 2002, 43,
5
2
2
013; (b) Kappe, C. O.; Shishkin, O. V.; Uray, G.; Verdino, P. Tetrahedron
000, 56, 1859; (c) Bose, D. S.; Kumar, R. K.; Fatima, L. A. Synlett 2004,
79; (d) De, S. K.; Gibbs, R. A. Synthesis 2005, 1748; (e) Pasha, M. A.;
We thank the Austrian Science Fund (Project I18-N07) for
supporting this work.
Swamy, N. R.; Jayashankara, V. P. Indian J. Chem., Sect. B 2005, 44, 823;
f) Srinivas, K. V. N. S.; Das, B. Synthesis 2004, 2091; (g) Bose, D. S.;
(
References and notes
Sudharshan, M.; Chavhan, S. W. ARKIVOC 2005, iii, 228; (h) Salehi,
P.; Dabiri, M.; Zolfigol, M. A.; Fard, M. A. B. Tetrahedron Lett. 2003,
44, 2889; (i) Bose, D. S.; Chary, M. V.; Mereyala, H. B. Heterocycles
2006, 68, 1217; (j) Rafiee, E.; Jafari, H. Bioorg. Med. Chem. Lett. 2006,
16, 2463; (k) Russowsky, D.; Canto, R. F. S.; Sanches, S. A. A.; D’Oca,
M. G. M.; de Fatima, A.; Pilli, R. A.; Kohn, L. K.; Antonio, M. A.;
Ernesto de Carvalho, J. Bioorg. Chem. 2006, 34, 173; (l) Godoi, M. N.;
Costenaro, H. S.; Kramer, E.; Machado, P. S.; Montes, D.; Marcelo, G.;
Russowsky, D. Quim. Nova 2005, 28, 1010.
1
2
. For reviews on DoE, see: (a) Tye, H. Drug Discov. Today 2004, 9, 485; (b)
Gooding, O. W. Curr. Opin. Chem. Biol. 2004, 8297.
. (a) Montgomery, D. C. Design and Analysis of Experiments, 6th ed.; John
Wiley and Sons: New York, NY, 2005; (b) Haaland, P. D. Experimental
Design in Biotechnology; Marcel Dekker: New York, NY, 1989.
3
12. For an enantioselective synthesis of monastrol, see: Huang, Y.; Yang, F.;
Zhu, C. J. Am. Chem. Soc. 2005, 127, 16386.
(
13. Yb(OTf)
3
ꢁH
2
O (ꢂ97% purity), 5 g for 79.10V; LaCl
3
ꢁH O (ꢂ98.5%
2
4
. (a) Kappe, C. O. Angew. Chem., Int. Ed. 2004, 43, 6250; (b) Kappe, C. O.;
Stadler, A. Microwaves in Organic and Medicinal Chemistry; Wiley-VCH:
Weinheim, 2005; (c) Microwaves in Organic Synthesis, 2nd ed.; Loupy,
A., Ed.; Wiley-VCH: Weinheim, 2006.
purity), 25 g for 14.30V (Aldrich Chemical Company).
2
14. R is a statistical parameter, which defines the goodness of fit of the
2
model. The closer to 1 this value is the better the fit. Q defines the good-
ness of prediction of the model. Again this should be as close to 1 as pos-
2
2
5
. (a) Larhed, M.; Hallberg, A. Drug Discov. Today 2001, 6, 406; (b)
Wathey, B.; Tierney, J.; Lidstr o¨ m, P.; Westman, J. Drug Discov. Today
sible. Only a model with good R and Q can be reliably used in
a predictive sense.
2002, 7, 373; (c) Al-Obeidi, F.; Austin, R. E.; Okonya, J. F.; Bond,
15. Stadler, A.; Kappe, C. O. J. Chem. Soc., Perkin Trans. 2 2000, 1363.